Details of the Drug

General Information of Drug (ID: DM9DR13)

Drug Name
PCAR-019
Indication
Disease Entry ICD 11 Status REF
Acute lymphocytic leukaemia 2B33.3 Phase 1/2 [1]
B-cell prolymphocytic leukaemia 2A82.1 Phase 1/2 [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [1]
Diffuse large B-cell lymphoma 2A81 Phase 1/2 [1]
Follicular lymphoma 2A80 Phase 1/2 [1]
Mantle cell lymphoma 2A85.5 Phase 1/2 [1]
⏷ Show the Full List of Indication(s)
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D0M0CO
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute lymphocytic leukaemia
ICD Disease Classification 2B33.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma